Related Experiment Video
Updated: Jan 25, 2026

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Published on: December 20, 2024
Bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer
1Orthopaedic Oncologic Unit, "Palazzo Baleani" Cancer Centre, Policlinico Umberto I, Rome, Italy, andrea.piccioli2013@libero.it.
Abstract:
Bisphosphonate represents a well-established treatment option in the management of metastatic bone disease and bone loss/osteoporosis in women with breast cancer. These drugs reduce osteoclast. Some bisphosphonate also have osteoblastic function leading to a reducted bone turnover and thereby skeletal-related events. The aim of this review is to evaluate the bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer. Based on the proven effect of bone protection during adjuvant endocrine therapy, new treatment guidelines recommend the routine use of bisphosphonates to prevent bone loss during adjuvant therapy, which may likely become the standard practice.
Related Concept Videos
Cancer
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Patient-centered Care
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

